PREMERA | BLUE CROSS

An Independent Licensee of the Blue Cross Blue Shield Association

MEDICAL POLICY – 8.01.521

Radioembolization for Primary and Metastatic Tumors of the Liver

BCBSA Ref. Policy:	8.01.43		
Effective Date:	Oct. 1, 2023	RELATED MEDICAL POLICIES:	
Last Revised:	Sept. 11, 2023	7.01.95	Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors
Replaces:	8.01.43	7.01.133	Microwave Tumor Ablation
		8.01.11	Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING
RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

Introduction

Embolization is a procedure to block blood flow. Combined with radiation, it is a way to treat cancer in the liver in some situations. In this procedure a catheter (a long, thin, hollow tube) is inserted in an artery near the groin. It's threaded to the tumor's blood supply. Tiny radioactive particles are released into the artery that feeds the tumor. The particles travel into the tumor and block off — embolize — the blood supply feeding the tumor, causing it to shrink. The radiation works to kill the cancer cells. The radiation dissipates in a few weeks and the particles stay in the liver permanently. The radiation usually doesn't affect the healthy liver tissue around the tumor very much. This policy describes when radioembolization may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Service	Medical Necessity

Radioembolization	**Radioembolization may be considered medically necessary in the following situations:**
	• Treatment of primary hepatocellular carcinoma that is unresectable and limited to the liver (size of tumor(s) does not exceed total tumor size of 8 cm, and individual with good performance status)
	OR
	• Treatment of primary hepatocellular carcinoma as a bridge to liver transplantation
	OR
	• Treatment of primary intrahepatic cholangiocarcinoma in individuals with unresectable tumors
	OR
	• Treatment of hepatic metastases from neuroendocrine tumors (carcinoid and noncarcinoid) with diffuse and symptomatic disease when systemic therapy has failed to control symptoms (symptoms related to excess hormone production)
	OR
	• Treatment of unresectable hepatic metastases from colorectal carcinoma, melanoma (ocular or cutaneous), or breast cancer with the following characteristics:
	  ○ That are both progressive and diffuse in individuals with liver-dominant disease, **and**
	  ○ That are refractory to chemotherapy or are not candidates for chemotherapy or other systemic therapies

Service	Investigational
Radioembolization	**Radioembolization is considered investigational for all other hepatic metastases except as noted in the Medical Necessity section above.**

Service	Investigational
	Radioembolization is considered investigational for all other indications not described in the Medical Necessity section above.

Documentation Requirements

The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include office visit notes that contain the relevant history and physical supporting ANY of the following situations:
• Individual with primary liver cancer that cannot be removed by surgery and limited to the liver (size of tumor(s) does not exceed total tumor size of 8 cm , and individual with good performance status)
• Treatment for hepatocellular carcinoma before a liver transplant
• Treatment of primary intrahepatic cholangiocarcinoma that cannot be removed by surgery
• Treatment of hepatic metastases from neuroendocrine tumors (carcinoid and noncarcinoid) with diffuse and symptomatic disease when systemic therapy has failed to control symptoms (symptoms related to excess hormone production)
• Treatment of hepatic metastases from breast, colorectal, or melanoma (ocular or cutaneous) that cannot be removed by surgery with the following characteristics:
  ○ That are progressive and unresectable in individual liver dominant disease
AND
  ○ That failed chemotherapy or are not candidates for chemotherapy or other systemic therapies

Coding

The coding for radioembolization may depend on the medical specialty providing the therapy.

Code	Description
CPT	
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction.
75894	Transcatheter therapy, embolization, any method, radiological supervision and interpretation

Code	Description
79445	Radiopharmaceutical therapy, by intra-arterial particulate administration
HCPCS	
C2616	Brachytherapy source, nonstranded, yttrium-90, per source
S2095	Transcatheter occlusion or embolization for tumor destruction, percutaneous, any method, using ytrrium-90 microspheres

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

There is little information on the safety or efficacy of repeated radioembolization treatments or on the number of treatments that should be administered.

Radioembolization should be reserved for individuals with adequate functional status (Eastern Cooperative Oncology Group Performance Status 0-2), adequate liver function and reserve, Child-Pugh class A or B, and liver-dominant metastases.

Symptomatic disease from metastatic neuroendocrine tumors refers to symptoms related to excess hormone production.

Definition of Terms

Child-Pugh Score: This score is used to assess the prognosis of chronic liver disease, usually cirrhosis.

Eastern Cooperative Oncology Group (ECOG): The ECOG performance status is used to assess an individual's disease progression and how the disease impacts the individual's activities of daily living (ADLs). **http://www.ecog.org/** (Accessed March 8, 2023)

Evidence Review

Description

Radioembolization (RE), also referred to as selective internal radiotherapy, delivers small beads (microspheres) impregnated with yttrium 90 intra-arterially via the hepatic artery. The microspheres, which become permanently embedded, are delivered to tumors preferentially because the hepatic circulation is uniquely organized, whereby tumors greater than 0.5 cm rely on the hepatic artery for blood supply while the normal liver is primarily perfused via the portal vein. Radioembolization has been proposed as a therapy for multiple types of primary and metastatic liver tumors.

Background

Treatments for Hepatic and NeuroEndocrine Tumors

The use of external-beam radiotherapy and the application of more advanced radiotherapy approaches (e.g., intensity-modulated radiotherapy) may be of limited use in individuals with multiple diffuse lesions due to the low tolerance of the normal liver to radiation compared with the higher doses of radiation needed to kill the tumor.

Various nonsurgical ablative techniques have been investigated that seek to cure or palliate unresectable hepatic tumors by improving locoregional control. These techniques rely on extreme temperature changes (cryosurgery or radiofrequency ablation), particle and wave physics (microwave or laser ablation), or arterial embolization therapy including chemoembolization, bland embolization, or radioembolization.

Radioembolization

Radioembolization (referred to as selective internal radiotherapy in older literature) delivers small beads (microspheres) impregnated with yttrium-90 (Y90) intra-arterially via the hepatic artery. The microspheres, which become permanently embedded, are delivered to tumors preferentially because the hepatic circulation is uniquely organized, whereby tumors greater than 0.5 cm rely on the hepatic artery for blood supply while the normal liver is primarily perfused via the portal vein. Y90 is a pure beta-emitter with a relatively limited effective range and a short half-life that helps focus the radiation and minimize its spread. Candidates for radioembolization are initially examined by hepatic angiogram to identify and map the hepatic arterial system. At that time, a mixture of technetium 99-labeled albumin particles are delivered

via the hepatic artery to simulate microspheres. Single-photon emission computed tomography is used to detect possible shunting of the albumin particles into the gastrointestinal or pulmonary vasculature.

Currently, two commercial forms of Y90 microspheres are available: a glass sphere (TheraSphere) and a resin sphere (SIR-Spheres). Noncommercial forms are mostly used outside the U. S. While the commercial products use the same radioisotope (Y90) and have the same target dose (100 gray), they differ in microsphere size profile, base material (i.e., resin vs glass), and size of commercially available doses. The physical characteristics of the active and inactive ingredients affect the flow of microspheres during injection, their retention at the tumor site, spread outside the therapeutic target region, and dosimetry calculations. The U.S. Food and Drug Administration (FDA) granted premarket approval of SIR-Spheres for use in combination with 5-floxuridine chemotherapy by hepatic arterial infusion to treat unresectable hepatic metastases from colorectal cancer. In contrast, TheraSphere's glass sphere was approved under a humanitarian device exemption for use as monotherapy to treat unresectable hepatocellular carcinoma. In 2007, this humanitarian device exemption was expanded to include individuals with hepatocellular carcinoma who have partial or branch portal vein thrombosis. For these reasons, results obtained with a product do not necessarily apply to another commercial (or non-commercial) products (see **Regulatory Status** section).

Summary of Evidence

For individuals who have unresectable hepatocellular carcinoma (HCC) who receive RE or RE with a liver transplant, the evidence includes primarily retrospective and prospective nonrandomized studies, with limited evidence from randomized controlled trials (RCTs). The relevant outcomes are overall survival (OS), functional outcomes, quality of life (QOL), and treatment-related morbidity. Nonrandomized studies have suggested that RE has high response rates compared with historical controls. Two small pilot RCTs have compared RE with alternative therapies for HCC, including transarterial chemoembolization (TACE) and drug-eluting bead (DEB)-TACE. Both trials reported similar outcomes for RE compared with alternatives. Evidence from nonrandomized studies has demonstrated that RE can permit successful liver transplantation in certain individuals. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unresectable intrahepatic cholangiocarcinoma (ICC) who receive RE, the evidence includes a phase 2 study and case series. The relevant outcomes are OS, functional outcomes, QOL, and treatment-related morbidity. Comparisons of these case series to case series of alternative treatments have suggested that RE for primary ICC has response rates

similar to those seen with standard chemotherapy. Due to high study heterogeneity, it is difficult to identify individuals that are most likely to benefit from treatment. A phase 2 study of RE with chemotherapy in the first-line setting reported a response rate of 39% and a disease control rate of 98%. The efficacy of RE in the neoadjuvant setting is being evaluated in an ongoing follow-up RCT. Another phase 2 study evaluating RE with or without subsequent chemotherapy in patients without prior treatment with chemotherapy or radiation found overall response rates of 25% and 16.7% in those who received RE with and without chemotherapy, respectively; the disease control rates were 75% and 58.3% amongst those who received RE with and without chemotherapy, respectively. However, at this time, the evidence is not yet sufficiently robust to draw definitive conclusions about treatment efficacy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unresectable neuroendocrine tumors who receive RE, the evidence includes an open-label phase 2 study, retrospective reviews, and case series, some of which have compared RE with other transarterial liver-directed therapies. The relevant outcomes are OS, functional outcomes, QOL, and treatment-related morbidity. This evidence has suggested that RE provides outcomes similar to standard therapies and historical controls for individuals with neuroendocrine tumor-related symptoms or progression of the liver tumor. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unresectable intrahepatic metastases from colorectal carcinoma (CRC) and prior treatment failure who receive RE, the evidence includes several small- to moderate-sized RCTs, prospective trials, and retrospective studies using a variety of comparators, as well as systematic reviews of these studies. The relevant outcomes are OS, functional outcomes, QOL, and treatment-related morbidity. While studies of individuals with prior chemotherapy failure have methodologic problems and have not shown definitive superiority of RE compared with alternatives in terms of survival benefit, they tend to show greater tumor response and significantly delayed disease progression, particularly with combined use of RE and chemotherapy. For example, the Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH) RCT found significantly prolonged primary endpoints of progression free survival (PFS) (Hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.54 to 0.88) and hepatic PFS (HR, 0.59; 95% CI, 0.46 to 0.77) with combined RE and chemotherapy in individuals who had progressed on first-line chemotherapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have unresectable intrahepatic metastases from other cancers (e.g., breast, melanoma, pancreatic) who receive RE, the evidence includes nonrandomized studies. The

relevant outcomes are OS, functional outcomes, QOL, and treatment-related morbidity. These studies have shown significant tumor response; however, improvement in survival has not been demonstrated in controlled comparative studies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in **Table 1**.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Hepatocellular carcinoma			
Ongoing			
NCT04736121[a]	A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)	100	Jun 2025 (recruiting)
NCT04522544[a]	A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design	84	Sep 2024 (recruiting)
NCT04069468[a]	A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France (PROACTIF)	500	Jan 2025 (recruiting)
NCT05377034[a]	A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II Trial to Compare Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab) Versus Selective Internal Radiation Therapy (SIRT-Y90) Followed by Placebo in Patients With Locally Advanced Hepatocellular Carcinoma (HCC) (STRATUM)	176	Nov 2025 (recruiting)

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT05063565[a]	An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial to Evaluate The Efficacy and Safety Of TheraSphere Followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC) (ROWAN)	150	Apr 2026 (suspended)
Unpublished			
NCT04090645	A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer	187	Apr 2021 (completed)
NCT01176604	Protocol for Use of TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma	305	Aug 2021 (completed)
NCT01556490[a]	A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC) (STOP-HCC)	526	Apr 2022 (completed)
NCT02072356	A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma	800	Jun 2021 (completed)
Metastatic colorectal cancer			
NCT05195710[a]	Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases	50	Mar 2024 (recruiting)
Intrahepatic Cholangiocarcinoma Unpublished			
NCT02807181[a]	SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)	89	Oct 2022 (completed)
Neuroendocrine Tumors			
NCT04362436[a]	A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the Treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs) (ArTisaN)	24	Sep 2024 (recruiting)
Metastatic uveal melanoma			
NCT02936388	Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis (SirTac)	108	Dec 2022 (recruiting)
Metastatic Breast Cancer			

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT05315687[a]	Safety and Efficacy of Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy	50	Jul 2025 (not yet recruiting)

NCT: national clinical trial. [a] Denotes industry-sponsored or cosponsored trial.

Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the policy conclusions.

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2015 Input

In response to requests, input was received from three physician specialty societies (with five individual responses) and one academic medical center (with four individual responses), for a total of 9 respondents, while this policy was under review in 2015. There was consensus supporting the use of radioembolization (RE) for hepatic metastases from melanoma, particularly ocular melanoma, and breast cancer. There was also consensus supporting the use of RE for treatment of primary intrahepatic cholangiocarcinoma. There was less consensus on the use of RE for hepatic metastases from other specific tumor types, including pancreatic cancer. However, many reviewers supported the use of RE for treatment of other radiosensitive tumors metastatic to the liver with the liver-limited or liver-dominant disease for symptom palliation or prolongation of survival.

2010-2011 Input

In response to requests, input was received from two physician specialty societies (with five individual responses) and six academic medical centers, for a total of 11 respondents, while this

policy was under review in 2010 and again in 2011. For the 2011 review, input was received from two physician specialty societies and three academic medical centers; all but one academic medical center had provided input in 2010. There was strong support for the use of RE in individuals with primary hepatocellular carcinoma, as a bridge to liver transplant in hepatocellular carcinoma, and in neuroendocrine tumors. There was also strong support for use of RE in individuals with liver metastases from colorectal cancers and support for its use in individuals with liver metastases from other cancers but with less consensus than for colorectal metastases. Those providing input were split as to whether RE should be used as monotherapy or in combination with other agents.

The support for the use of RE in individuals with chemotherapy-refractory colorectal metastases was primarily to prolong time to tumor progression and subsequent liver failure (a major cause of morbidity and mortality in this patient population), potentially prolonging survival. Additional support for the use of RE in this setting was for the palliation of symptoms from tumor growth and tumor bulk.

Support for the use of RE for liver metastases from tumors other than colorectal or neuroendocrine was generally limited to a number of specific tumor types, in particular, ocular melanoma, cholangiocarcinoma, breast, and pancreas.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Radiology et al

In 2021, the American College of Radiology issued a practice parameter jointly developed with the American Brachytherapy Society, the American College of Nuclear Medicine, the American Society for Radiation Oncology, the Society of Interventional Radiology, and the Society of Nuclear Medicine and Molecular Imaging addressing the use of RE for the treatment of liver malignancies with glass- or resin-based yttrium-90 microspheres.[100] The guidelines provided indications and contraindications for treatment as follows:

- "Indications for both agents include but are not limited to the following:
    - The presence of unresectable or inoperable primary or secondary liver malignancies (particularly colorectal cancer and neuroendocrine tumor metastases). The tumor burden should be liver dominant, not necessarily exclusive to the liver. Individuals should also have a performance status that will allow them to benefit from such therapy.
    - A life expectancy of at least 3 months."
- "Absolute contraindications include the following:
    - Inability to catheterize the hepatic artery
    - Fulminant liver failure
    - Initial mapping angiography and/or technetium-99m macroaggregated albumin (MAA) hepatic arterial perfusion scintigraphy demonstrating nontarget deposition to the gastrointestinal organs that cannot be corrected by angiographic techniques.
    - Pretreatment hepatic arterial administration with technetium-99m MAA demonstrative of unfavorable (or unacceptable) shunt function between the liver and the pulmonary parenchyma. This shunt fraction must not be greater than acceptable limits specific to each brachytherapy device.
    - Active hepatic infection
    - Therapy during pregnancy may possibly be an option in extraordinary circumstances and with multidisciplinary consult and considerations."
- "Relative contraindications include the following:
    - Excessive tumor burden in the liver with great than 50-70% of the parenchyma replaced by tumor. In the setting of more extensive tumor burden, treatment can be considered if synthetic hepatic function is preserved.
    - Total bilirubin greater than 2 mg/dL (in the absence of obstructive cause), which indicates severe liver function impairment. Nonobstructive bilirubin elevations may indicate that liver metastases have caused liver impairment to the degree that risks outweigh benefits for this therapy. In contrast, individuals with hepatocellular carcinoma (HCC) and elevated bilirubin may be treated with radioembolization if a segmental or subsegmental infusion can be performed.

- Prior radiation therapy to the liver or upper abdomen that included a significant volume of the liver (clinical judgment by the [authorized user] required).
- Care must be employed when individuals are on systemic therapies that may potentiate or may alter the impact of radioembolization and should use caution when combining therapies."

American Society of Clinical Oncology

The 2023 American Society of Clinical Oncology (ASCO) guidelines for the treatment of metastatic colorectal cancer (mCRC) makes the following relevant recommendation: [101]

- "SIRT [selective internal radiation therapy] is not routinely recommended for patients with mCRC and unilobar or bilobar metastases of the liver (Type: Evidence-based, harms outweigh benefits; Evidence quality: Low; Strength of recommendation: Weak)."

National Comprehensive Cancer Network

Primary Hepatocellular Carcinoma

The National Comprehensive Cancer Network (NCCN) guidelines (v.1.2023) on the treatment of hepatocellular carcinoma indicate that the use of arterially directed therapies, including transarterial bland embolization, transarterial chemoembolization, and drug-eluting beads transarterial chemoembolization, and RE with yttrium-90 microspheres may be appropriate provided that the arterial blood supply can be isolated without excessive nontarget treatment. Individuals should be considered for locoregional therapy if they are not candidates for potential curative treatments (resection, transplantation, and for small lesions, ablative strategies). RE with yttrium-90 microspheres has an increased risk of radiation-induced liver disease in individuals with bilirubin levels greater than 2 mg/dL. Delivery of 205 Gy or more to the tumor may be associated with increased overall survival. A dose of greater than 400 Gy to 25% of the liver or less in patients with Child-Pugh A liver function is recommended. RE may be more appropriate in some individuals with advanced HCC, specifically individual with segmental or lobar portal vein, rather than main portal vein, thrombosis.[29]

Metastatic Neuroendocrine Tumors

The NCCN guidelines (v.2.2022) on the treatment of neuroendocrine tumors recommend consideration of transarterial radioembolization (TARE) for lobar or segmental disease distribution and in patients with prior Whipple surgery or biliary tract instrumentation.[102] TARE is better tolerated than transarterial embolization/transarterial chemoembolization, but late radioembolization-induced chronic hepatotoxicity may occur in long-term survivors, and is particularly a concern among patients undergoing bilobar radioembolization.

Metastatic Colon Cancer

The NCCN guidelines (v.2.2023) on the treatment of colon cancer provides a consensus recommendation that: "…arterial-directed catheter therapy, in particular yttrium-90 microsphere selective internal radiation, is an option in highly selected individuals with chemotherapy-resistant/-refractory disease and with predominant hepatic metastases." RE may also be considered "when hepatic metastatic disease is not optimally resectable based on insufficient remnant liver volume…" The guidelines also note that "further investigation is necessary to identify the role of radioembolization at earlier stages of disease, particularly in patients with right-sided primary origin."[103]

Metastatic Uveal Melanoma

The NCCN guidelines (v.1.2023) on the treatment of uveal melanoma state the following regarding RE: "Further study is required to determine the appropriate patients for and risk and benefits of this approach."

National Institute for Health and Care Excellence

Primary Hepatobiliary Carcinoma

The July 2013 NICE interventional procedures guidance on selective internal radiation therapy for primary hepatocellular carcinoma states that the evidence for efficacy and safety are adequate for use with normal arrangements. However, "uncertainties remain about its comparative effectiveness, and clinicians are encouraged to enter eligible patients into trials comparing the procedure against other forms of treatment."[105]

In March 2021, a NICE technology appraisal guidance on sSIRTs for treating hepatocellular carcinoma was published, providing specific evidence-based recommendations for the use of

SIR-Spheres (Sirtex), TheraSphere (Boston Scientific), and QuiremSpheres (Quirem Medical).[106] The guidance states that RE with SIR-Spheres or TheraSphere is recommended as an option for treating unresectable advanced hepatocellular carcinoma in adults only if "used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and the company provides [the microspheres] according to the commercial arrangement." The guidance also stated that "clinical trial data for these SIRTs compared with other treatment options are limited. But, compared with sorafenib, SIRTs may have fewer and more manageable adverse effects, which can improve quality of life." The use of QuiremSpheres, imageable holmium-166 microspheres, was not recommended due to reduced clinical efficacy compared to sorafenib and higher cost. QuiremSpheres received its CE mark in April 2015 in Europe and is not commercially available in the U.S.

Primary Intrahepatic Cholangiocarcinoma

The October 2018 NICE interventional procedures guidance on sSIRT for unresectable primary intrahepatic cholangiocarcinoma state that there are "well-recognized, serious but rare safety concerns. Evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research."[107]

Metastatic Colon Cancer

The March 2020 NICE interventional procedures guidance on SIRT for unresectable colorectal metastases in the liver states that "in people who cannot tolerate chemotherapy or have liver metastases that are refractory to chemotherapy, there is evidence of efficacy, but this is limited, particularly for important outcomes such as quality of life. Therefore, in these people, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research."[10]

Medicare National Coverage

There is no national coverage determination.

Regulatory Status

Currently, two forms of Y90 microspheres have been approved by the FDA.

In 1999, TheraSphere (Boston Scientific; previously manufactured by Nordion, under license by BTG International), a glass sphere system, was approved by the FDA through the humanitarian drug exemption process for radiotherapy or as a neoadjuvant treatment to surgery or transplantation in individuals with unresectable hepatocellular carcinoma who can have placement of appropriately positioned hepatic arterial catheters (H980006).

On March 17, 2021, TheraSphere received approval through the premarket approval process for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in individuals with unresectable hepatocellular carcinoma, Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status (P200029).

In 2002, SIR-Spheres (Sirtex Medical), a resin sphere system, was approved by the FDA through the premarket approval process for the treatment of inoperable colorectal cancer metastatic to the liver (P990065).

FDA product code: NAW.

References

1. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. May 18 2002; 359(9319): 1734-9. PMID 12049862
2. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. May 2002; 35(5): 1164-71. PMID 11981766
3. Tao R, Li X, Ran R, et al. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget. Jan 17 2017; 8(3): 5460-5473. PMID 27705924
4. Pollock RF, Brennan VK, Shergill S, et al. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Expert Rev Anticancer Ther. Mar 2021; 21(3): 341-349. PMID 33131346
5. Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. Jan 24 2020; 1: CD011313. PMID 31978267
6. Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. Jun 2015; 35(6): 1715-21. PMID 25443863

7. Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. Apr 2015; 38(2): 352-60. PMID 25373796

8. Venerito M, Pech M, Canbay A, et al. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with 90 Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. J Nucl Med. Dec 2020; 61(12): 1736-1742. PMID 32358087

9. Yang B, Liang J, Qu Z, et al. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS One. 2020; 15(2): e0227475. PMID 32074102

10. Ludwig JM, Zhang D, Xing M, et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90 Y-radioembolization for hepatocellular carcinoma. Eur Radiol. May 2017; 27(5): 2031-2041. PMID 27562480

11. Lobo L, Yakoub D, Picado O, et al. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. Nov 2016; 39(11): 1580-1588. PMID 27586657

12. Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol. Jun 28 2016; 8(18): 770-8. PMID 27366304

13. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. Apr 2009; 19(4): 951-9. PMID 18989675

14. Dhondt E, Lambert B, Hermie L, et al. 90 Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology. Jun 2022; 303(3): 699-710. PMID 35258371

15. Facciorusso A, Bargellini I, Cela M, et al. Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel). Apr 07 2020; 12(4). PMID 32272656

16. Padia SA, Johnson GE, Horton KJ, et al. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study. J Vasc Interv Radiol. Jun 2017; 28(6): 777-785.e1. PMID 28365172

17. Soydal C, Arslan MF, Kucuk ON, et al. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. Nucl Med Commun. Jun 2016; 37(6): 646-9. PMID 26905317

18. Oladeru OT, Miccio JA, Yang J, et al. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol. Jun 2016; 7(3): 433-40. PMID 27284477

19. El Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. Liver Int. Feb 2015; 35(2): 627-35. PMID 25040497

20. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. Mar 2015; 35(3): 1036-47. PMID 24750853

21. Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. Mar 01 2010; 116(5): 1305-14. PMID 20066715

22. Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology. Jan 2018; 67(1): 381-400. PMID 28859222

23. Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. Dec 2016; 151(6): 1155-1163.e2. PMID 27575820

24. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. Aug 2014; 61(2): 309-17. PMID 24681342

25. Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. Nov 2021; 74(5): 2342-2352. PMID 33739462

26. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): TheraSphere. **https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029B.pdf**. Accessed August 7, 2023.

27. Pellegrinelli J, Chevallier O, Manfredi S, et al. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience. Diagnostics (Basel). Jan 14 2021; 11(1). PMID 33466706

28. Gabr A, Kulik L, Mouli S, et al. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology. Mar 2021; 73(3): 998-1010. PMID 32416631

29. Zori AG, Ismael MN, Limaye AR, et al. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation. Am J Clin Oncol. May 2020; 43(5): 325-333. PMID 32079854

30. Tohme S, Sukato D, Chen HW, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol. Nov 2013; 24(11): 1632-8. PMID 24160821

31. Ramanathan R, Sharma A, Lee DD, et al. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. Jul 15 2014; 98(1): 100-6. PMID 24503764

32. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. Aug 2009; 9(8): 1920-8. PMID 19552767

33. National Organization for Rare Disorders. Rare Disease Database: Cholangiocarcinoma. 2020; **https://rarediseases.org/rare-diseases/cholangiocarcinoma**. Accessed August 7, 2023.

34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. Version 1.2022. **https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf**. Accessed August 4, 2022.

35. Schartz DA, Porter M, Schartz E, et al. Transarterial Yttrium-90 Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. Jun 2022; 33(6): 679-686. PMID 35219834

36. Edeline J, Lamarca A, McNamara MG, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treat Rev. Sep 2021; 99: 102258. PMID 34252720

37. Yu Q, Liu C, Pillai A, et al. Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis. Liver Cancer. Sep 2021; 10(5): 433-450. PMID 34721506

38. Mosconi C, Solaini L, Vara G, et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol. May 2021; 44(5): 728-738. PMID 33709272

39. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. Feb 2015; 111(2): 213-20. PMID 25176325

40. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. Jan 01 2020; 6(1): 51-59. PMID 31670746

41. Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. Oct 2020; 27(10): 3729-3737. PMID 32472411

42. Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. J Vasc Interv Radiol. Jul 2020; 31(7): 1035-1043.e2. PMID 32473757

43. Jia Z, Paz-Fumagalli R, Frey G, et al. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. J Cancer Res Clin Oncol. Mar 2017; 143(3): 481-489. PMID 27826686

44. Mosconi C, Gramenzi A, Ascanio S, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. Jul 26 2016; 115(3): 297-302. PMID 27336601

45. Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol. Sep 2015; 22(9): 3102-8. PMID 25623598

46. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. Aug 2013; 24(8): 1227-34. PMID 23602420

47. Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. Feb 2012; 35(1): 105-16. PMID 21431970

48. Haug AR, Heinemann V, Bruns CJ, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging. Jun 2011; 38(6): 1037-45. PMID 21308371

49. Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. Feb 2010; 17(2): 484-91. PMID 19876691

50. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. Oct 15 2008; 113(8): 2119-28. PMID 18759346

51. Paprottka KJ, Galie F, Ingrisch M, et al. Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors. Cancers (Basel). Oct 27 2021; 13(21). PMID 34771563

52. Sarwar A, Ali A, Ljuboja D, et al. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. Nov 2021; 32(11): 1560-1568. PMID 34454031

53. Cancer.Net. Neuroendocrine Tumors: Statistics. February 2022; **https://www.cancer.net/cancer-types/neuroendocrine-tumors/statistics**. Accessed August 7, 2023.

54. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. Sep 01 2008; 113(5): 921-9. PMID 18618495

55. Ngo L, Elnahla A, Attia AS, et al. Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes. Ann Surg Oncol. Apr 2021; 28(4): 1950-1958. PMID 33393019

56. Frilling A, Clift AK, Braat AJAT, et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB (Oxford). Jul 2019; 21(7): 773-783. PMID 30733049

57. Devcic Z, Rosenberg J, Braat AJ, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med. Sep 2014; 55(9): 1404-10. PMID 25012459

58. Egger ME, Armstrong E, Martin RC, et al. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. J Am Coll Surg. Apr 2020; 230(4): 363-370. PMID 32032719

59. Engelman ES, Leon-Ferre R, Naraev BG, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. Mar 2014; 43(2): 219-25. PMID 24518499

60. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. Jun 2008; 247(6): 1029-35. PMID 18520231

61. Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. Apr 2010; 97(4): 537-43. PMID 20205229

62. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. Jun 2008; 31(3): 271-9. PMID 18525307

63. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. Jul 01 2012; 83(3): 887-94. PMID 22137020

64. Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. Apr 2012; 35(2): 334-42. PMID 21847708

65. Peker A, Cicek O, Soydal C, et al. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol. Jan-Feb 2015; 21(1): 54-9. PMID 25430526

66. Jia Z, Paz-Fumagalli R, Frey G, et al. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. J Gastroenterol Hepatol. Sep 2017; 32(9): 1617-1623. PMID 28132407

67. Fan KY, Wild AT, Halappa VG, et al. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials. Sep 2016; 50: 143-9. PMID 27520932

68. Tice J. Selective internal radiation therapy or radioembolization for inoperable liver metastases from colorectal cancer San Francisco, CA: California Technology Assessment Forum; 2010.

69. Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol. Apr 2014; 140(4): 537-47. PMID 24318568

70. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. Dec 2001; 12(12): 1711-20. PMID 11843249

71. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. Aug 10 2010; 28(23): 3687-94. PMID 20567019

72. Rosenbaum CE, Verkooijen HM, Lam MG, et al. Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J Nucl Med. Nov 2013; 54(11): 1890-5. PMID 24071510

73. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. Nov 01 2004; 88(2): 78-85. PMID 15499601

74. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev. Oct 07 2009; (4): CD007045. PMID 19821394

75. Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol. Dec 10 2021; 39(35): 3897-3907. PMID 34541864

76. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. May 20 2016; 34(15): 1723-31. PMID 26903575

77. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. Sep 2017; 18(9): 1159-1171. PMID 28781171

78. Wolstenholme J, Fusco F, Gray AM, et al. Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer. Int J Cancer. Aug 15 2020; 147(4): 1078-1085. PMID 31840815

79. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. Jan 2010; 138(1): 52-64. PMID 19766639

80. Mokkarala M, Noda C, Malone C, et al. Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Versus Radioembolization (TARE) for Patients With Colorectal Cancer Liver Metastases. Anticancer Res. Jun 2019; 39(6): 3071-3077. PMID 31177151

81. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. Oct 2012; 35(5): 1066-73. PMID 21800231

82. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. Mar-Apr 2010; 16(2): 163-75. PMID 20404614

83. Aarts BM, Munoz FMG, Wildiers H, et al. Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol. Dec 2021; 44(12): 1868-1882. PMID 34322751

84. Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review. World J Gastrointest Oncol. Feb 15 2020; 12(2): 228-236. PMID 32104553

85. Ridouani F, Soliman MM, England RW, et al. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer. Eur J Radiol. Mar 2021; 136: 109539. PMID 33476965

86. Davisson NA, Bercu ZL, Friend SC, et al. Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer. J Vasc Interv Radiol. Jun 2020; 31(6): 925-933. PMID 32307310

87. Alexander H, Wen D, Chu M, et al. Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review. Br J Radiol. Jan 01 2022; 95(1129): 20210200. PMID 34757824

88. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). Apr 2020; 22(4): 497-505. PMID 31791894

89. Gonsalves CF, Eschelman DJ, Adamo RD, et al. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology. Oct 2019; 293(1): 223-231. PMID 31453767

90. Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. Am J Clin Oncol. Feb 2017; 40(1): 27-34. PMID 25089529

91. Eldredge-Hindy H, Ohri N, Anne PR, et al. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. Am J Clin Oncol. Apr 2016; 39(2): 189-95. PMID 24441583

92. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. Feb 2011; 196(2): 468-73. PMID 21257902

93. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. Jul 2009; 27(6): 682-90. PMID 19219675

94. Klingenstein A, Haug AR, Zech CJ, et al. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol. Feb 2013; 36(1): 158-65. PMID 22526099

95. Piduru SM, Schuster DM, Barron BJ, et al. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. J Vasc Interv Radiol. Jul 2012; 23(7): 943-8. PMID 22609292

96. Ruohoniemi DM, Zhan C, Wei J, et al. Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. J Vasc Interv Radiol. Aug 2020; 31(8): 1233-1241. PMID 32741550

97. Michl M, Haug AR, Jakobs TF, et al. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Oncology. 2014; 86(1): 24-32. PMID 24401529

98. Miller MD, Sze DY, Padia SA, et al. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study. J Vasc Interv Radiol. Jun 2018; 29(6): 867-873. PMID 29724518

99. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2021. **https://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf**. Accessed August 4, 2022.

100. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 1.2022. **https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf**. Accessed August 4, 2022.

101. National Comprehensive Cancer Network. Melanoma: Uveal. Version 2.2022. **https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf**. Accessed August 4, 2022.

102. Hong K, Akinwande O, Bodei L, et al. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. Brachytherapy. May-Jun 2021; 20(3): 497-511. PMID 33824051

103. National Institute for Health and Care Excellence. Selective internal radiation therapy for primary hepatocellular carcinoma Interventional procedures guidance [IPG460]. July, 2013. **https://www.nice.org.uk/guidance/ipg460**. Accessed August 7, 2023.

104. National Institute for Health and Care Excellence. Selective internal radiation therapies for treating hepatocellular carcinoma. Technology appraisal guidance [TA688]. March 2021. **https://www.nice.org.uk/guidance/ta688**. Accessed August 7, 2023.

105. National Institute for Health and Care Excellence. Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma Interventional procedures guidance [IPG630]. October, 2018. **https://www.nice.org.uk/guidance/ipg630**. Accessed August 7, 2023

106. National Institute for Health and Care Excellence. Selective internal radiation therapy for unresectable colorectal metastases in the liver Interventional procedures guidance [IPG672]. March 2020. **https://www.nice.org.uk/guidance/ipg672**. Accessed August 7, 2023.

History

Date	Comments
03/30/04	Add to Therapy Section - New Policy
03/08/05	Replace Policy - Policy reviewed; reference added; policy statement unchanged.
03/14/06	Replace Policy - Policy reviewed; reference added; policy statement unchanged.
06/02/06	Scope and Disclaimer Update - No other changes.
11/14/06	Replace Policy - Policy reviewed by Oncology Advisory panel and recommended for adoption on October 26, 2006.
04/10/07	Cross Reference Update - No other changes.
06/15/07	Cross Reference Update - No other changes.
10/09/07	Replace Policy - Policy updated with literature review through February 2007; policy statement unchanged. Additional humanitarian device exemption indication for glass spheres for primary hepatocellular cancer noted. Reference added. CPT coding updated.
03/19/08	Code Update - ICD-9 diagnosis code 197.7 added.
11/11/08	New PR Policy - Policy updated with literature search. Policy statement changed to medically necessary with bulleted criteria. This was changed to keep consistent with

Date	Comments
	the TACE (8.01.505) policy statement. Reviewed and recommended by OAP on August 21, 2008. Policy status changed from BC to PR, replacing BC.8.01.43.
08/11/09	Replace Policy - Policy updated with literature search; no change to the policy statement. References added. Reviewed and recommended by OAP August 2009.
12/14/10	Replace Policy - Policy updated with literature search; no change to policy statement. NCCN 2010 reference added. Reviewed and recommended by OAP November 18, 2010.
10/11/11	Replace Policy – Policy updated with literature review; no change in policy statement.
02/27/12	Related Policies updated; 7.01.133 added.
05/22/12	Replace policy. Policy updated with literature review through February 2012; no change in policy statements. Physician specialty society input and references added. Clinical Trials and NCCN Guidelines updated.
11/15/12	Replace Policy. Minor edit for clarification of the acronym for RE and SIRT. Verified NCCN hyperlinks still active. Policy statement unchanged. Reviewed and recommended by OAP November 2012.
05/28/13	Replace policy. Policy updated with literature review. Policy reorganized. No change in policy statements. References added, removed, renumbered. ICD-10 codes added.
07/16/13	Update Related Policies. Add 8.01.528.
12/23/13	Coding Update. CPT code 37204 discontinued effective 12/31/13.
03/14/14	Coding update. CPT code 37243, effective 1/1/14, added to the policy.
03/27/14	Coding update; CPT codes 37243 removed from policy. It does not apply to this policy, see 8.01.521.
09/03/14	Annual Review. Added a policy statement indicating all other indications not listed as medically necessary are investigational. Policy Guidelines added including Definition of Terms. Policy updated with literature review through June, 2014. Rationale section reformatted. References 15-16, 22-23, 32, 42-43, 48, 51 added. References 4-6 and 49-51 updated; others renumbered/removed. Policy statement added as noted. Coding update: CPT code 77776 added to the policy; ICD-9 and ICD-10 codes removed from policy – they are not utilized in adjudication of the policy.
09/11/14	Update Related Policies. Add 7.01.95.
10/13/15	Annual Review. Policy updated with literature review. Medically necessary indications were added for the treatment of hepatocellular carcinoma as a bridge to hepatic transplant. The indications for treatment of hepatic metastases from breast cancer or melanoma with liver dominant disease and intrahepatic cholangiocarcinoma were moved from medically necessary to investigational. These changes harmonize the medical necessity indications for this policy and 8.01.505- Transcatheter Arterial Chemoembolization (TACE) as a Treatment for Primary or Metastatic Liver Malignancies. References updated.

Date	Comments
07/01/16	Annual Review, approved June 14, 2016. Prioritized annual review. Policy reformatted for clarity. Coverage added for symptomatic palliation of hepatic metastatic tumors. Criteria added for qualification for use as bridge to liver transplant in hepatocellular carcinomas. Discussion section clarified to support policy. Clinical trials section simplified.
07/08/16	Minor edit to investigational statement for clarity; intent is unchanged.
10/01/16	Interim Review, approved September 13, 2016. Policy updated with literature review through June 10, 2016; references 12-13, 47, and 49 added. Investigational statement added for previously untreated metastatic colorectal cancer. CPT codes 77776 and 77778 removed; deleted code as of 1/1/16 and reviewed by AIM, respectively.
10/01/17	Annual Review, approved September 5, 2017. No changes to policy statements. Policy updated with literature review through June 2017: references added 8-11, 15, 21, 31-32 and 56.
03/01/18	Coding update, removed CPT code 77399.
10/01/18	Annual Review, approved September 20, 2018. Policy updated with literature review through May 2018; references 16, 28, and 73 added. Policy statements unchanged.
11/01/19	Annual Review, approved October 4, 2019. Policy updated with literature review through May 2019; references on NCCN updated. Policy statements unchanged.
04/01/20	Delete policy, approved March 10, 2020. This policy will be deleted effective July 2, 2020, and replaced with InterQual criteria for dates of service on or after July 2, 2020.
06/10/20	Interim Review, approved June 9, 2020, effective June 10, 2020. This policy is reinstated immediately and will no longer be deleted or replaced with InterQual criteria on July 2, 2020.
08/01/2020	Delete policy, approved July 14, 2020. This policy is replaced with 8.01.43.
10/01/20	Interim Review, approved September 17, 2020. Policy updated with literature review through May 2020; references added. Policy statements unchanged.
05/18/21	Update Related Policies. Corrected Renumbered Policy 8.01.505 to 8.01.11
10/01/21	Annual Review, approved September 2, 2021. Policy updated with literature review through May 27, 2021; references added. Policy statements unchanged.
09/01/22	Annual Review, approved August 22, 2022. Policy updated with literature review through June 22, 2022; references added. NCCN and NICE guidelines updated. Policy statements unchanged. Added HCPCS code C2616.
04/01/23	Policy renumbered, approved March 14, 2023 from 8.01.43 to 8.01.521 Radioembolization for Primary and Metastatic Tumors of the Liver. Changed tumor size from 3 cm or larger to "size of tumor(s) does not exceed total tumor size of 8 cm" in the first policy bullet for medically necessary radioembolization treatment of primary hepatocellular carcinoma that is unresectable. Other minor edits made for

Date	Comments
	clarification only, policy intent unchanged. Changed the wording from "patient" to "individual" throughout the policy for standardization where appropriate.
10/01/23	Annual Review, approved September 11, 2023. Policy updated with literature review through May 26, 2023; references added. Minor editorial refinements to policy statements; intent unchanged.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2023 Premera All Rights Reserved.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

Discrimination is Against the Law

Premera Blue Cross (Premera) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). Premera provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator — Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-4535, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@Premera.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html.

Washington residents: You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at https://fortress.wa.gov/oic/onlineservices/cc/pub/complaintinformation.aspx.

Alaska residents: Contact the Alaska Division of Insurance via email at insurance@alaska.gov, or by phone at 907-269-7900 or 1-800-INSURAK (in-state, outside Anchorage).

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-722-1471 (TTY: 711).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-722-1471 (TTY: 711).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-722-1471 (TTY：711）。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-722-1471 (TTY: 711).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-722-1471 (TTY: 711) 번으로 전화해 주십시오.

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-722-1471 (телетайп: 711).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 800-722-1471 (TTY: 711).

MO LOU SILAFIA: Afai e te tautala Gagana fa'a Sāmoa, o loo iai auaunaga fesoasoan, e fai fua e leai se totogi, mo oe, Telefoni mai: 800-722-1471 (TTY: 711).

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທຣ 800-722-1471 (TTY: 711).

注意事項：日本語を話される場合、無料の言語支援をご利用いただけます。800-722-1471 （TTY:711）まで、お電話にてご連絡ください。

PAKDAAR: Nu saritaem ti Ilocano, ti serbisyo para ti baddang ti lengguahe nga awanan bayadna, ket sidadaan para kenyam. Awagan ti 800-722-1471 (TTY: 711).

УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки. Телефонуйте за номером 800-722-1471 (телетайп: 711).

ប្រយ័ត្ន៖ បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតឈ្នួល គឺអាចមានសំរាប់បំរើអ្នក។ ចូរ ទូរស័ព្ទ 800-722-1471 (TTY: 711)។

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፣ በነጻ ሊያግዝዎት ተዘጋጀተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 800-722-1471 (መስማት ለተሳናቸው: 711).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-722-1471 (TTY: 711).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-722-1471 (رقم هاتف الصم والبكم: 711).

ਧਿਆਨ ਦਿਓ: ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-722-1471 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

เรียน: ถ้าคุณพูดภาษาไทยคุณสามารถใช้บริการช่วยเหลือทางภาษาได้ฟรี โทร 800-722-1471 (TTY: 711).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-722-1471 (TTY: 711).

UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-722-1471 (TTY: 711).

ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 800-722-1471 (TTY: 711).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-722-1471 (ATS : 711).

ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-722-1471 (TTY: 711).

ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-722-1471 (TTY: 711).

توجه: اگر به زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-722-1471 (TTY: 711) تماس بگیرید.

Premera Blue Cross is an independent licensee of the Blue Cross Blue Shield Association serving businesses and residents of Alaska and Washington State, excluding Clark County.
052493 (07-01-2021)